12 Month Price Forecast For KVUE
Distance to KVUE Price Forecasts
KVUE Price Momentum
๐ค Considering Kenvue (KVUE)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: February 15, 2025 5:07 PM UTC
KVUE Analyst Ratings & Price Targets
Based on our analysis of 18 Wall Street analysts, KVUE has a neutral consensus with a median price target of $24.00 (ranging from $21.00 to $26.55). The overall analyst rating is Buy (7.1/10). Currently trading at $21.93, the median forecast implies a 9.4% upside. This outlook is supported by 6 Buy, 11 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Peter Grom at UBS, suggesting a 4.2% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
KVUE Analyst Consensus
KVUE Price Target Range
Latest KVUE Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for KVUE.
Date | Firm | Analyst | Rating | Change | Price Target |
---|---|---|---|---|---|
Feb 7, 2025 | Canaccord Genuity | Susan Anderson | Buy | Maintains | $24.00 |
Feb 7, 2025 | UBS | Peter Grom | Neutral | Maintains | $21.00 |
Feb 3, 2025 | RBC Capital | Nik Modi | Sector Perform | Reiterates | $24.00 |
Jan 17, 2025 | Barclays | Lauren Lieberman | Equal-Weight | Maintains | $21.00 |
Jan 16, 2025 | UBS | Peter Grom | Neutral | Maintains | $23.00 |
Jan 15, 2025 | Citigroup | Filippo Falorni | Neutral | Maintains | $21.00 |
Jan 6, 2025 | Piper Sandler | Overweight | Upgrade | $0.00 | |
Dec 12, 2024 | Deutsche Bank | Steve Powers | Hold | Downgrade | $24.00 |
Oct 22, 2024 | B of A Securities | Anna Lizzul | Buy | Maintains | $27.00 |
Oct 11, 2024 | JP Morgan | Andrea Teixeira | Overweight | Maintains | $25.00 |
Sep 24, 2024 | Jefferies | Keith Devas | Buy | Initiates | $27.00 |
Sep 24, 2024 | RBC Capital | Nik Modi | Sector Perform | Downgrade | $24.00 |
Sep 23, 2024 | Piper Sandler | Korinne Wolfmeyer | Neutral | Maintains | $21.00 |
Aug 7, 2024 | UBS | Peter Grom | Neutral | Maintains | $22.00 |
Aug 7, 2024 | RBC Capital | Nik Modi | Outperform | Reiterates | $24.00 |
Aug 7, 2024 | JP Morgan | Andrea Teixeira | Overweight | Maintains | $24.00 |
Aug 7, 2024 | Deutsche Bank | Steve Powers | Buy | Maintains | $24.00 |
Jul 25, 2024 | Deutsche Bank | Steve Powers | Buy | Maintains | $23.00 |
Jul 22, 2024 | JP Morgan | Andrea Teixeira | Overweight | Maintains | $22.00 |
Jul 11, 2024 | Citigroup | Neutral | Maintains | $0.00 |
Stocks Similar to Kenvue Inc. Common Stock
The following stocks are similar to Kenvue based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Kenvue Inc. Common Stock (KVUE) Financial Data
Kenvue Inc. Common Stock has a market capitalization of $42.05B with a P/E ratio of 40.6x. The company generates $15.46B in trailing twelve-month revenue with a 6.9% profit margin.
Revenue growth is -0.4% quarter-over-quarter, while maintaining an operating margin of +19.9% and return on equity of +9.9%.
Valuation Metrics
Growth & Margins
Financial Health
๐ฅ Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.

Kenvue Inc. Common Stock (KVUE) Company Overview
About Kenvue Inc. Common Stock
Consumer health products across multiple segments.
Kenvue Inc. generates revenue through three main segments: Self Care, Skin Health and Beauty, and Essential Health. Each segment offers a range of well-known consumer health products, catering to various health and wellness needs, which allows the company to capture a wide market and generate consistent sales.
Founded in 2022 and headquartered in Skillman, New Jersey, Kenvue leverages established brand names such as Tylenol, Neutrogena, and Listerine, positioning itself as a trusted provider in the consumer health sector.
Company Information
Sector
Consumer Defensive
Industry
Household & Personal Products
Employees
22,000
CEO
Mr. Thibaut Mongon
Country
United States
IPO Year
2023
Website
www.kenvue.comKenvue Inc. Common Stock (KVUE) Latest News & Analysis
Kenvue Inc. (NYSE: KVUE) executives will present at the CAGNY Conference on February 19, 2025. A live webcast and replay will be available on their investor website.
Kenvue's leadership presentation at a key industry conference could indicate strategic direction and growth prospects, influencing investor sentiment and stock performance.
Kenvue Is A Mediocre Candidate
7 days agoKenvue, with a market cap of $37.96 billion, faces profitability challenges despite revenue growth. Recent results show declining net income and EBITDA, leading to a 'hold' rating.
Kenvue's mixed financial results and struggles with profitability despite growth signal potential risks. A low valuation may attract interest, but weak fundamentals suggest caution.
Kenvue: An Intriguing Turnaround
5 days agoKenvue's stock has underperformed post-IPO with reduced guidance for 2023 and 2024. Strong brands and activist investor support suggest potential for future improvement.
Kenvue's stock dip and guidance cuts raise concerns, but strong brands and activist investor backing hint at potential recovery, making it a stock to watch for future growth.
Kenvue projected 2025 adjusted profit below Wall Street estimates due to a stronger dollar and weak demand for cough and cold products like Tylenol and Benadryl.
Kenvue's lower 2025 profit forecast indicates potential revenue challenges, impacting investor confidence and possibly leading to stock price declines.
Kenvue's Q4 Sales Miss, Margins Improve
9 days agoKenvue (KVUE) reported mixed Q4 and full-year earnings, with adjusted EPS of $0.26 meeting market consensus on February 6.
Kenvue's mixed earnings report signals stability with EPS meeting expectations, but highlights potential concerns about growth, influencing investor confidence and stock performance.
Kenvue, Inc. (NYSE:KVUE) will hold its Q4 2024 earnings conference call on February 6, 2025, at 8:00 AM ET, featuring key executives and analysts from major financial institutions.
Kenvue's earnings call indicates financial performance insights, impacting stock valuation and investor sentiment. Analyst participation suggests significant interest in the company's outlook and strategy.
Frequently Asked Questions About KVUE Stock
What is Kenvue Inc. Common Stock's (KVUE) stock forecast for 2025?
Based on our analysis of 18 Wall Street analysts, Kenvue Inc. Common Stock (KVUE) has a median price target of $24.00. The highest price target is $26.55 and the lowest is $21.00.
Is KVUE stock a good investment in 2025?
According to current analyst ratings, KVUE has 6 Buy ratings, 11 Hold ratings, and 0 Sell ratings. The stock is currently trading at $21.93. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for KVUE stock?
Wall Street analysts predict KVUE stock could reach $24.00 in the next 12 months. This represents a 9.4% increase from the current price of $21.93. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Kenvue Inc. Common Stock's business model?
Kenvue Inc. generates revenue through three main segments: Self Care, Skin Health and Beauty, and Essential Health. Each segment offers a range of well-known consumer health products, catering to various health and wellness needs, which allows the company to capture a wide market and generate consistent sales.
What is the highest forecasted price for KVUE Kenvue Inc. Common Stock?
The highest price target for KVUE is $26.55 from at , which represents a 21.1% increase from the current price of $21.93.
What is the lowest forecasted price for KVUE Kenvue Inc. Common Stock?
The lowest price target for KVUE is $21.00 from Peter Grom at UBS, which represents a -4.2% decrease from the current price of $21.93.
What is the overall KVUE consensus from analysts for Kenvue Inc. Common Stock?
The overall analyst consensus for KVUE is neutral. Out of 18 Wall Street analysts, 6 rate it as Buy, 11 as Hold, and 0 as Sell, with a median price target of $24.00.
How accurate are KVUE stock price projections?
Stock price projections, including those for Kenvue Inc. Common Stock, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.